- Home
- CRWD vs MRK Comparison
CRWD vs MRK Comparison
Compare CRWD & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | MRK |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3B | 281.2B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CRWD | MRK |
|---|---|---|
| Price | $701.68 | $128.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 48 | 17 |
| Target Price | ★ $507.00 | $125.59 |
| AVG Volume (30 Days) | 3.2M | ★ 8.6M |
| Earning Date | 06-02-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 0.11 | N/A |
| Revenue | $4,812,005,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $24.85 | $3.61 |
| Revenue Next Year | $21.40 | $5.41 |
| P/E Ratio | $6,165.82 | ★ N/A |
| Revenue Growth | ★ 21.71 | 1.31 |
| 52 Week Low | $342.72 | $76.66 |
| 52 Week High | $785.66 | $125.96 |
Technical Indicators
Market Signals| Indicator | CRWD | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 70.38 |
| Support Level | $463.35 | $112.68 |
| Resistance Level | $785.66 | N/A |
| Average True Range (ATR) | 31.68 | 3.07 |
| MACD | -7.46 | 0.91 |
| Stochastic Oscillator | 81.82 | 97.44 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).